Get the Stockscreener App
1.74
1.75%
0.03
Cel-Sci Corp. stock is traded at $1.74, with a volume of 69,286.
It is up +1.75% in the last 24 hours and up +17.57% over the past month.
CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company's Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.
See More
Previous Close:
$1.71
Open:
$1.69
24h Volume:
69,286
Relative Volume:
0.16
Market Cap:
$30.60M
Revenue:
Net Income/Loss:
$-22.70M
P/E Ratio:
-0.50
EPS:
-3.4798
Net Cash Flow:
$-16.66M
1W Performance:
-10.77%
1M Performance:
+17.57%
6M Performance:
-60.27%
1Y Performance:
-82.79%
1-Day Range:
$1.66
$1.78
1-Week Range:
$1.66
$1.98
52-Week Range:
$0.89
$10.24
Cel-Sci Corp. Stock (CVM) Company Profile
Name
Cel-Sci Corp.
Sector
Industry
Phone
703-506-9460
Address
8229 Boone Boulevard, Suite 802, Vienna, VA
Compare CVM vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVM
Cel-Sci Corp.
|
1.74 | 30.60M | 0 | -22.70M | -16.66M | -3.4798 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cel-Sci Corp. Stock (CVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-02-15 | Initiated | Dawson James | Buy |
Cel-Sci Corp. Stock (CVM) Latest News
Cel-Sci Corporation (CVM) Jumps 11.98% to $2.71 as Buyers Push Toward ResistanceETF AUM Growth - https://www.siam.in/
Form 4 CEL-SCI Corp For: 1 October By Investing.com - Investing.com Australia
CEL SCI Corp CSO Eyal Talor Purchases 1,165 Shares of Common Stock - Kalkine Media
A 1,165-share award brings Eyal Talor’s direct CEL SCI CORP (CVM) holdings to 10,483 shares. - stocktitan.net
A 2,082-share award brings CEL SCI CORP (CVM) CFO Patricia B. Prichep's direct holding to 19,571 shares. - stocktitan.net
A 2,621-share grant leaves CEL SCI CORP (CVM) CEO holding 318,763 shares directly. - stocktitan.net
Cel-Sci Corporation (CVM) Stock Analysis: Unpacking The 738% Potential Upside - DirectorsTalk Interviews
CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology - Investing News Network
CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology - Yahoo Finance
CEL-SCI Corp (CVM) Key Financial Ratios – Valuation, Profitability & More - Value Research
Cel Sci CEO Geert Kersten purchases $138,000 in shares By Investing.com - Investing.com Nigeria
Cel Sci CEO Geert Kersten purchases $138,000 in shares By Investing.com - Investing.com South Africa
Cel Sci CEO Geert Kersten purchases $138,000 in shares By Investing.com - Investing.com UK
CEL SCI (CVM) CEO adds 100K restricted shares to his stake - Stock Titan
Cel-Sci (CVM) Outlook: Ends Up by 3.14% at $1.64 for the Current Session; Key Range: the Price Remains Bounded by the Supplied Support and Resistance at the CloseHagopian Line - vinanet.vn
CEL-SCI Company Profile & Introduction - Moomoo
CEL-SCI closes $2.5M offering to fund Multikine - scanx.trade
CEL-SCI Q3 Results: Per-share loss narrows 65% YoY to $(0.47) - scanx.trade
Cel-Sci shareholders elect directors and approve compensation plans at annual meeting - Investing.com
CEL SCI director granted 110K options at $1.49 | CVM Insider Trading - Stock Titan
CEL-SCI director granted 110K options at $1.49 | CVM Insider Trading - Stock Titan
CEL-SCI (NYSE: CVM) awards CEO 300,000 options over 3 years - Stock Titan
CEL-SCI (NYSE: CVM) awards Cipriano 80K options vesting over 3 years - Stock Titan
CEL-SCI (CVM) awards CSO Talor Eyal 250,000 stock options - Stock Titan
Form 8K CEL-SCI Corp For: 17 August By Investing.com - Investing.com Nigeria
CEL-SCI (NYSEAMERICAN: CVM) CFO lands new 2036 stock option grant - Stock Titan
Form 8K CEL-SCI Corp For: 17 August By Investing.com - Investing.com Canada
Form 8K CEL-SCI Corp For: 17 August By Investing.com - Investing.com India
Form 8K CEL-SCI Corp For: 17 August By Investing.com - Investing.com UK
CEL-SCI (CVM) Advances Multikine Trial Amid Low Valuation and Gu - GuruFocus
CEL-SCI Reports Fiscal Third Quarter 2026 Results - Yahoo Finance
CEL-SCI Reports Fiscal Third Quarter 2026 Results - Investing News Network
Cel-Sci: Fiscal Q3 Earnings Snapshot - marketscreener.com
Cel-Sci: Fiscal Q3 Earnings Snapshot - AOL.com
Cel-Sci: Fiscal Q3 Earnings Snapshot - cbs19news.com
Cel-Sci: Fiscal Q3 Earnings Snapshot - KTVB
CEL-SCI (CVM) faces going concern risk amid $16.6M loss and $6.5M cash - Stock Titan
CEL-SCI Corp (CVM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CEL-SCI Corp (CVM) Stock News Today - tradingkey.com
CEL-SCI publishes study on Multikine cancer treatment biomarkers - Investing.com
CEL-SCI (CVM) Advances Oral Cancer Immunotherapy Amid Challengin - GuruFocus
Before surgery, Multikine cut disease-progression risk 49% in study - Stock Titan
CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study - Yahoo Finance
CEL-SCI Trial Reports 73% Five-Year Survival in Low PD-L1 Oral Cancer - Stock Titan
Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients - Yahoo Finance
Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients - Investing News Network
Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients - Business Wire
CEL-SCI Corp (CVM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CEL-SCI Corp (CVM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CEL-SCI Corp (CVM) Institutional Confidence - TradingKey
Cel-Sci Corp. Stock (CVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cel-Sci Corp. Stock (CVM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KERSTEN GEERT R | Chief Executive Officer |
May 14 '26 |
Buy |
1.20 |
300,000 |
360,000 |
311,547 |
| KERSTEN GEERT R | Chief Executive Officer |
May 13 '26 |
Buy |
1.19 |
100,000 |
119,000 |
222,497 |
| KERSTEN GEERT R | Chief Executive Officer |
Jan 22 '26 |
Buy |
5.26 |
38,023 |
200,001 |
120,815 |
| KERSTEN GEERT R | Chief Executive Officer |
Dec 04 '25 |
Buy |
5.96 |
8,389 |
49,998 |
81,794 |
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):